Drug intelligence / Profile preview

RVM-V001 + RVM-V002

Development stage: Unknown
Lead developer: RVAC Medicines
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RVM-V001 + RVM-V002 is a bivalent COVID-19 mRNA vaccine combination being developed by RVAC Medicines. It consists of two separate mRNA vaccine candidates administered together: RVM-V001 targeting the original (ancestral) strain of SARS-CoV-2 and RVM-V002 targeting the Omicron variant. The combination is designed as a potential booster candidate to prevent COVID-19 in individuals who have previously received mRNA-based or inactivated virus COVID-19 vaccines.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on RVM-V001 + RVM-V002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVM-V001 + RVM-V002.

Explore the full profile